Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303)
暂无分享,去创建一个
S. Nomura | A. Sato | K. Muro | A. Ohtsu | Ken Kato | T. Doi | T. Kojima | T. Nishina | H. Hara | M. Wakabayashi | S. Takahashi
[1] M. Suntharalingam,et al. Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial , 2017, JAMA oncology.
[2] Sung-Bae Kim,et al. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. , 2017, The Lancet. Oncology.
[3] I. Treilleux,et al. Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group , 2017, British Journal of Cancer.
[4] A. Ochiai,et al. Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma , 2017, BMC Cancer.
[5] Benjamin J. Raphael,et al. Integrated genomic characterization of oesophageal carcinoma , 2017, Nature.
[6] C. Gridelli,et al. Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[7] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[8] P. Petrow,et al. PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients , 2015, Clinical Cancer Research.
[9] N. Lu,et al. PIK3CA Gene Mutations and Overexpression: Implications for Prognostic Biomarker and Therapeutic Target in Chinese Esophageal Squamous Cell Carcinoma , 2014, PloS one.
[10] J. Bendell,et al. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors , 2014, Investigational New Drugs.
[11] M. Robson,et al. Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors , 2014, Cancer science.
[12] Razelle Kurzrock,et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. , 2014, Cell reports.
[13] A. González-Angulo,et al. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. , 2013, Cancer treatment reviews.
[14] C. Hurt,et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. , 2013, The Lancet. Oncology.
[15] H. Baba,et al. PIK3CA Mutation Is Associated with a Favorable Prognosis among Patients with Curatively Resected Esophageal Squamous Cell Carcinoma , 2013, Clinical Cancer Research.
[16] Razelle Kurzrock,et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Jordi Rodon,et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Razelle Kurzrock,et al. PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors , 2011, Molecular Cancer Therapeutics.
[19] M. Wilkerson,et al. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. , 2010, Cancer cell.
[20] F. Lordick,et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] A. Ohtsu,et al. Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors , 2009, Japanese journal of clinical oncology.
[22] L. Cantley,et al. PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.
[23] H. Sasaki,et al. PIK3CA mutation status in Japanese esophageal squamous cell carcinoma. , 2008, The Journal of surgical research.
[24] Hans Clevers,et al. Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity. , 2005, Human molecular genetics.
[25] R. DePinho,et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. , 2004, Cancer cell.
[26] H. Yamana,et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). , 2001, Japanese journal of clinical oncology.
[27] H. Watanabe,et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. , 1992, Japanese journal of clinical oncology.
[28] S. Andreola,et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.